Literature DB >> 7694032

'Binge' cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen.

R Spangler1, E M Unterwald, M J Kreek.   

Abstract

Other workers have established that cocaine injections increase the levels of dynorphin peptides in the caudate putamen and substantia nigra of the rat brain. Using a quantitative solution hybridization protection assay for mRNA, we detected a significant increase in the concentration of prodynorphin mRNA in caudate putamen extracts of rats injected with cocaine following a 'binge' administration pattern designed to mimic human cocaine abuse. Increased prodynorphin mRNA was observed at the earliest time-point studied (50 h) and the lowest dose (10 mg/kg/day) of cocaine tested and persisted through the 14 day period studied. No prodynorphin mRNA was detected in the substantia nigra.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694032     DOI: 10.1016/0169-328x(93)90133-a

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  65 in total

1.  kappa-Opioid tolerance and dependence in cultures of dopaminergic midbrain neurons.

Authors:  F C Dalman; K L O'Malley
Journal:  J Neurosci       Date:  1999-07-15       Impact factor: 6.167

2.  Acute withdrawal from chronic escalating-dose binge cocaine administration alters kappa opioid receptor stimulation of [35S] guanosine 5'-O-[gamma-thio]triphosphate acid binding in the rat ventral tegmental area.

Authors:  A P Piras; Y Zhou; S D Schlussman; A Ho; M J Kreek
Journal:  Neuroscience       Date:  2010-05-07       Impact factor: 3.590

3.  Repeated cocaine self-administration causes multiple changes in rat frontal cortex gene expression.

Authors:  Willard M Freeman; Karen Brebner; Kruti M Patel; Wendy J Lynch; David C S Roberts; Kent E Vrana
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

4.  Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

5.  A single cocaine exposure enhances both opioid reward and aversion through a ventral tegmental area-dependent mechanism.

Authors:  Joseph A Kim; Kelly A Pollak; Gregory O Hjelmstad; Howard L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-02       Impact factor: 11.205

6.  Effects of withdrawal from chronic escalating-dose binge cocaine on conditioned place preference to cocaine and striatal preproenkephalin mRNA in C57BL/6J mice.

Authors:  Yong Zhang; Stefan D Schlussman; Eduardo R Butelman; Ann Ho; Mary Jeanne Kreek
Journal:  Neuropharmacology       Date:  2012-04-04       Impact factor: 5.250

7.  Regulation of opioid gene expression in the rat brainstem by 3,4-methylenedioxymethamphetamine (MDMA): role of serotonin and involvement of CREB and ERK cascade.

Authors:  Manuela Di Benedetto; Sussy del Carmen Bastías Candia; Claudio D'Addario; Elena Elettra Porticella; Chiara Cavina; Sanzio Candeletti; Patrizia Romualdi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-12-23       Impact factor: 3.000

8.  Exposure to cocaine alters dynorphin-mediated regulation of excitatory synaptic transmission in nucleus accumbens neurons.

Authors:  Ping Mu; Peter A Neumann; Jaak Panksepp; Oliver M Schlüter; Yan Dong
Journal:  Biol Psychiatry       Date:  2010-10-27       Impact factor: 13.382

9.  Kappa opioid inhibition of somatodendritic dopamine inhibitory postsynaptic currents.

Authors:  Christopher P Ford; Michael J Beckstead; John T Williams
Journal:  J Neurophysiol       Date:  2006-11-22       Impact factor: 2.714

10.  Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain.

Authors:  Francesco Leri; Yan Zhou; Benjamin Goddard; AnneMarie Levy; Derek Jacklin; Mary Jeanne Kreek
Journal:  Eur Neuropsychopharmacol       Date:  2008-11-06       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.